
Fini la chute de cheveux ? De nouvelles innovations bousculent les soins capill…
Chaque matin, des cheveux dans la brosse. Un geste banal, presque automatique, jusqu’au jour où le miroir devient moins indulgent. Et si la solution …
Hair Loss Community Abuzz as Influencer Introduces New Treatment London, UK – Tom Gillbanks, a prominent figure in the online hair loss community, has announced a significant update to his personal treatment protocol, introducing pyrilutamide (also known as KX-826) to his regimen. The move has sparked considerable interest among his followers, as Gillbanks aims to document his experience with the experimental compound. Gillbanks, who has openly shared his journey to combat male pattern baldness, currently adheres to a comprehensive treatment plan that includes 1mg of finasteride six times weekly, 0.5mg of dutasteride once weekly, 10% topical minoxidil daily, and 0.025% tretinoin daily. He states that these treatments have been effective in stabilizing his hair loss since he began early at age 23. The decision to incorporate pyrilutamide stems from Gillbanks' commitment to a "science-based page" and his desire to "keep my hair as long as possible." Pyrilutamide is an androgen receptor antagonist, designed to compete with androgens like DHT at the hair follicle level, potentially reducing further damage. Gillbanks presented data from clinical trials of KX-826, noting that "the safety data on this is looking good" and that the "actual effects are looking promising, but not yet solid." He specifically highlighted a Phase III clinical trial for KX-826 that reached its primary endpoint, showing "satisfactory safety and tolerability" with no serious adverse events. However, he acknowledged that one study lacked a placebo control, making its results less definitive. He expressed optimism for ongoing higher-quality Phase III trials for a 1% strength solution, hoping for "good results with a higher dose." Distinguishing pyrilutamide from other experimental topical anti-androgens, Gillbanks noted its "way better safety data" compared to compounds like RU58841, which he claims was abandoned and lacks safety and efficacy data. Gillbanks emphasized that this is a personal experiment and not an endorsement for others to immediately adopt the treatment. "Am I telling you guys to start it too? No. I want to try it first and actually document the process," he stated. He reiterated his long-term goal: "Essentially, I just want to do as much as I can so I can have a chad head of hair at 70 years old." His primary motivation, he explained, is to "improve the quality of information in the hair loss community while at the same time hopefully improving my own hair loss journey."
Chaque matin, des cheveux dans la brosse. Un geste banal, presque automatique, jusqu’au jour où le miroir devient moins indulgent. Et si la solution …